RPRXHealthcare · BiotechnologyThe 8 Wall Street analysts covering Royalty Pharma plc hold a median 12-month price target of $66 — +11.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 87 of 100 as at 12 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Royalty Pharma plc on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (100): The share price has been relatively steady.
Issuance (33): The company has been issuing shares or taking on financing, diluting existing holders.
Size (7): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on RPRX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +11.8% from it.
Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 8 Sept 2026 | TD Cowen | Maintains | Buy | $65 → $68 |
| 7 Aug 2026 | JP Morgan | Maintains | Overweight | $58 → $62 |
| 7 Aug 2026 | JP Morgan | Maintains | Overweight | — |
| 13 July 2026 | TD Cowen | Maintains | Buy | $50 → $65 |
| 13 July 2026 | TD Cowen | Maintains | Buy | — |
| 7 May 2026 | Citigroup | Maintains | Buy | — |
| 7 May 2026 | JP Morgan | Maintains | Overweight | — |
| 21 Apr 2026 | UBS | Maintains | Buy | — |
| 10 Apr 2026 | Morgan Stanley | Maintains | Overweight | — |
| 30 Jan 2026 | UBS | Upgrade | Buy | — |
| 27 Jan 2026 | Citigroup | Maintains | Buy | — |
| 11 Dec 2025 | TD Cowen | Maintains | Buy | — |
| 10 Oct 2025 | Morgan Stanley | Maintains | Overweight | — |
| 30 Sept 2025 | Goldman Sachs | Initiates | Buy | — |
| 22 July 2025 | Citigroup | Maintains | Buy | — |
| 10 July 2025 | Morgan Stanley | Maintains | Overweight | — |
| 25 Oct 2024 | Citigroup | Maintains | Buy | — |
| 14 Aug 2024 | Goldman Sachs | Maintains | Buy | — |
| 11 July 2024 | Morgan Stanley | Maintains | Overweight | — |
| 3 June 2024 | UBS | Downgrade | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RPRX appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 11 Sept 2026, Royalty Pharma plc returned +62.9% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 24% of US stocks
Cheaper than 12% of US stocks
Cheaper than 27% of US stocks
Cheaper than 12% of US stocks
Higher than 65% of US stocks
Higher than 12% of US stocks
Higher than 79% of US stocks
Higher than 91% of US stocks
Higher than 72% of US stocks
Higher than 77% of US stocks
Higher than 37% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Royalty Pharma plc has a market value of $33.9B and an enterprise value of $37.2B.
Revenue in the twelve months to 30 June 2026: $2.5B. The latest quarter grew 16.5% year on year.
Net income over the same four quarters: $1.3B, a 53.2% net margin.
Diluted earnings per share, trailing twelve months: $1.46.
Free cash flow in the twelve months to 30 June 2026: $3.0B.
Royalty Pharma plc spent $321.8M on share buybacks and $399.1M on dividends in the twelve months to 30 June 2026.
Trailing P/E: 31.5×; forward P/E: 10.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 1.60%, paying out 49% of earnings.
Royalty Pharma plc employs 100 people — $25.4M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Royalty Pharma plc — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Royalty Pharma plc announced it will participate in several upcoming investor conferences during September 2026. The company made the announcement from New York on September 9, 2026.
Why it matters — Participation in investor conferences offers Royalty Pharma management a platform to communicate with the investment community, which RPRX watchers may track for updates or insights.
Novartis AG shares experienced one of their sharpest single-day drops in recent history on Tuesday, according to the report. The decline is described as having ripple effects across the company's biotech partners.
Why it matters — Since Royalty Pharma often holds royalty interests in partnered biotech assets, a meaningful decline at Novartis and its partners could warrant attention from RPRX watchers regarding related commercial performance.
Royalty Pharma announced that Novartis' Phase 3 HORIZON outcomes trial for pelacarsen did not meet its primary endpoint of reducing the risk of cardiovascular events in patients with atherosclerotic cardiovascular disease and elevated lipoprotein(a), compared to placebo. Novartis plans to present the trial data at an upcoming medical congress.
Why it matters — Since Royalty Pharma holds royalty interests in commercial and development-stage biopharmaceutical products, a failed Phase 3 trial for pelacarsen may affect the potential future royalty stream associated with the drug.
Seeking Alpha reports that Royalty Pharma is delivering solid portfolio execution, with management highlighting increased scalability for higher-value transactions and a strategic shift toward development-stage assets that yield higher IRRs. The company is capitalizing on biopharma inflows and cites upcoming positive catalysts that are expected to drive incremental royalty growth.
Why it matters — RPRX watchers would note the company's strong execution, raised guidance, and anticipated catalysts as indications that portfolio performance and royalty growth are expected to continue.
Seeking Alpha reports that Royalty Pharma delivered strong 2Q26 results, including 14% Royalty Receipts growth, 95% margins, and $728 million in operating cash flow. Management raised 2026 Portfolio Receipts guidance to $3.4–$3.5 billion, projecting 7–10% royalty growth despite headwinds such as Promacta erosion and IRA-related pressure.
Why it matters — For RPRX watchers, the raised guidance and strong cash-generative results affirm the company's durable compounding profile even amid known headwinds.
The 8 Wall Street analysts covering Royalty Pharma plc have a median 12-month price target of $66, with estimates ranging from $61 to $70. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 8 analysts covering Royalty Pharma plc, 7 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Royalty Pharma plc 87 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 12 Sept 2026, Royalty Pharma plc ranks 87 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (100 of 100).
No one can know that. What the data says: the median 12-month target from 8 analysts implies +11.8% from the last close, and Ticker Nerd's factor model ranks Royalty Pharma plc 87 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Royalty Pharma plc publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RPRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $61 to $70 over the next 12 months.
Royalty Pharma plc returned +62.9% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Royalty Pharma plc Class A Ordinary Shares represents an equity interest in Royalty Pharma plc, a New York-based biopharmaceutical royalty company. The company acquires and manages royalty interests tied to approved medicines and development-stage therapies, providing financing to drug developers and rights holders in exchange for a share of future product sales.
The most recent item we track (GlobeNewsWire, 9 Sept 2026): "Royalty Pharma to present at upcoming investor conferences". Royalty Pharma plc announced it will participate in several upcoming investor conferences during September 2026. The company made the announcement from New York on September 9, 2026.
Royalty Pharma plc Class A Ordinary Shares represents an equity interest in Royalty Pharma plc, a New York-based biopharmaceutical royalty company. The company acquires and manages royalty interests tied to approved medicines and development-stage therapies, providing financing to drug developers and rights holders in exchange for a share of future product sales. Its portfolio spans treatments in areas such as rare diseases, oncology, neuroscience, immunology, hematology, respiratory disease, infectious disease, and diabetes. Royalty Pharma also supports innovation by partnering with biotechnology and pharmaceutical companies, academic institutions, and research organizations across the life sciences sector. Through this model, the company serves as a specialized capital provider in the healthcare market, linking long-term funding needs with recurring revenue streams from commercialized therapies and pipeline assets.
CEO Mr. Pablo Legorreta · 100 employees · United States · https://www.royaltypharma.com
